Headquartered in Zrich, Switzerland, Baxters EMEA organization employs more than 14,700

people in over 35 countries. Sales in Europe, the Middle East and Africa (EMEA) amounted to
almost $4 billion in 2010.
In addition to over 25 sales and marketing sites in the region, Baxter has 22 production sites in
13 EMEA countries that manufacture products distributed to Baxter markets around the world.
Plants in Austria, Belgium, Ireland, Spain, Switzerland, the UK and others produce some 600
million units of Medication Delivery and Renal products each year, along with several million
tons of Bioscience products for biotherapeutics, hemophilia, biosurgery and vaccine therapy.
Baxter EMEA Organisation
BioScience
Medication Delivery
Renal
Science and Innovation
People
Awards and Recognition
Community and Sustainability
Baxter EMEA Organisation
Led by EMEA President Peter Nicklin, Baxter EMEA is organized into eight geographic
clusters, corresponding to the diverse market environments present in the region. Baxters two
business groups Bioscience and Medical Products (Medication Delivery and Renal) are
responsible for providing products and therapies for tens of thousands of patients across the
region.

BioScience
Baxter is the leading provider of products used in hemophilia therapy across the region. In
Russia, where Baxter is the Hemophilia market leader, the Russian government recently awarded
Baxter the largest tender in the companys history for the provision of plasma-derived FVIII
product.
Vaccine therapy is another driver of Baxter growth in EMEA. In 2010, Baxters innovative
influenza vaccine, PREFLUCEL, was launched in Austria and the Czech Republic before being
made available to other markets across the region in 2011.
Baxter also manufactures a variety of plasma-based biotherapeutic therapies for the treatment
of life-threatening conditions such as immune-system disorders. In this area, Baxter partners with
organizations such as the Jeffrey Modell Foundation (JMF) to help raise awareness amongst
patients and caregivers about immune deficiency illnesses and their treatments. In partnership
with the Foundation, Baxter has now opened almost a dozen JMF centres for Primary
Immunodeficiency research in countries across EMEA, including Belgium, Ireland, Italy, the
Netherlands and Switzerland.

Medication Delivery
Europe is the second largest market, after the United States, for Baxters Medication Delivery
products. A leading supplier of intravenous (IV) solutions in non-PVC flexible containers in
EMEA, the company produced almost 400 million IV bags in its EMEA manufacturing facilities
in 2010 alone. In addition, Baxter provides electronic and portable IV infusion pumps,
administration sets and access devices, which control the flow of IV fluids to patients.
The EMEA market leader for parenteral nutrition, Baxter has a complete portfolio of IV
administered nutrition products. These include nutrition solutions and innovative multi-chamber
container systems such as Olimel for adult critical care patients and Numeta, the first three-
chamber bag especially developed for at term and pre-term babies up to two years of age. With
Olimel, launched across Europe in 2010, and the rest of its nutrition offering, Baxter is able to
meet the needs of patients in both hospitals and at home. In fact, Baxter has over thirty years of
experience in home healthcare, with more than a third of its sales involving products to be used
by patients in the home.
In Anesthesia, Baxter is the only company to offer all three modern inhalation agents used in
general anesthesia: Suprane (desflurane), Sevoflurane and Isoflurane. In EMEA, the use of
Suprane (desflurane) continues to show double-digit growth, while Sevoflurane, the most
widely used inhalation anesthetic, is now registered and marketed in over a dozen European
countries as well as in several Middle Eastern markets.

Renal
Baxters Renal business provides products and services for end-stage renal disease and acute
kidney injury (reversible kidney failure). In addition to being a leader in renal home therapies for
peritoneal dialysis (PD), the business also distributes products for hemodialysis and continuous
renal replacement therapy (CRRT). Major manufacturing sites are based close to customers in
the region to facilitate delivery to home PD patients. Baxter has established home delivery
services in several countries, including Belgium, the Netherlands, the UK and Spain.

Science and Innovation
Europe is home to much of the research and development for Baxters global product portfolio.
With three major sites in Belgium (Alliance Park) and Austria (Vienna and Orth), Baxter EMEA
attracts and partners with Europes top scientists, researchers, engineers and academics on the
development of innovative new treatments and therapies for some of the most life-threatening
diseases and illnesses. Key Baxter products and therapies resulting from our European R & D
centres include twin bag packaging for continuous ambulatory peritoneal dialysis (CAPD), triple
chamber bags for parenteral nutrition, biocompatible solutions for peritoneal dialysis and a
resorbable bone substitute, just to name a few. In addition, Baxter partners with European
research universities and sponsors a number of scientific awards and fellowships aimed at
encouraging and supporting European-based medical research.

People
Fostering an inclusive and diverse work environment is one of the key principles of Baxter
EMEAs approach to talent management and employee engagement. Under the guidance of
EMEAs inclusion and diversity committee, a particular focus is increasing the number of
women in leadership positions in the region. As a result of positive employee feedback on
Baxters workplace environment, a number of EMEA sites - including Austria, Denmark,
France, Ireland, the Netherlands, Poland, Portugal, Spain and Switzerland - have been recognised
as one of their countrys Best Workplaces by local Great Place to Work organizations.

Awards and Recognition
In addition to the Great Place to Work recognition in several countries, Baxter EMEA sites have
also been recognized for outstanding achievement in environmental, corporate responsibility
(CSR) and scientific areas. A number of Baxters sites have achieved ISO EHS certification,
others have been recognized for their commitment to CSR, and still others, have been recognised
by the scientific community, such as Baxter Italy for its innovative Smartphone application for
hemophilia patients.

Community and Sustainability
In 2010, charitable giving from Baxter and The Baxter International Foundation, the
philanthropic arm of the corporation, totaled more than $80 million, with almost half a million
dollars given in charitable grants in EMEA. In addition, the region donated more than $9 million
in product to not-for-profit organizations and $8.3 million in business unit contributions to
charitable organizations addressing community needs.
Baxter employees are also actively engaged in the community. Through December 2010, Baxter
employees around the world logged over 163,000 volunteer hours as part of Baxters Global
Service Project. In EMEA, employees recorded 14,500 volunteer hours in the community
through involvement in a range of initiatives.




One of Baxters competitive strengths is its diverse technological expertise and commitment to
scientific innovation. The companys unique combination of capabilities in medical devices,
pharmaceuticals and biotechnology, including specialty biologics, sets it apart from other
companies in the healthcare industry.
Increasingly, technologies and scientific disciplines are converging, resulting in more new
therapies for patients and clinicians. The combination of these disciplines and technologies offers
great promise in addressing issues like medication errors and hospital-acquired infections, as
well as improving quality of life and clinical outcomes in chronic care and moving therapy from
the acute care center to outpatient and home care.
Baxter has research and development (R&D) centers around the world, including facilities in
Austria, Belgium, Japan and the United States. Principal areas of strategic focus for R&D
include recombinant and plasma-based therapeutics, vaccines, biosurgery regenerative medicine,
kidney dialysis, the formulation of small molecule drugs, enhanced packaging systems for
medication delivery, as well as parenteral nutrition.
2010 R&D Highlights
Core Technical Competencies
2010 R&D Highlights
In 2010, Baxters R&D investment of approximately $915 million focused on supporting late-
stage research, advancing early-stage and exploratory work and focusing on product
development across Baxters diverse portfolio. Baxter advanced 14 programs into late-stage
development including Phase III clinical trials, regulatory review or launch in 2010. The
company also has numerous early-stage programs in development that have the potential to
profoundly impact the treatment and delivery of care for chronic diseases like Alzheimers
disease, hemophilia, end-stage renal disease, immune deficiencies, as well as public health
threats like pandemic and seasonal influenza. The following includes some of Baxters 2010
R&D highlights.

Meeting Unmet Patient Needs
From Hospital to the Home
Advancing Innovation

Meeting Unmet Patient Needs
New discoveries to improve earlier diagnosis, prevention and treatment and provides new,
unrecognized solutions.
The launch of OLIMEL, the companys latest triple-chamber container system for
parenteral nutrition, across Europe. OLIMEL is the only product on the market with
formulations specifically designed to provide an optimal balance of protein and energy
while lowering the total fluid volume delivered.
The launch of TachoSil [Absorbable Fibrin Sealant Patch] in the United States for use
as an adjunct to hemostasis in cardiovascular surgery. TachoSil is the first and only
ready-to-use adjunctive hemostatic agent available in the United States that combines a
collagen patch with a coating of human coagulation factors.
Multiple advancements with GAMMAGARD LIQUID [Immune Globulin Intravenous
(Human)] 10% (marketed as KIOVIG in Europe) including:
o Approval in Europe, Canada and the U.S. for the first and only 30-gram dose vial.
This new dosage form is the most frequently prescribed dose and will enhance
user convenience.
o The completion of enrollment in a Phase III clinical trial for the treatment of
Multifocal Motor Neuropathy (MMN).
o Advancement of a Phase II clinical study for mild-to-moderate Alzheimer's
disease. The Phase II results represent the first study in Alzheimer's disease where
all three measures cognitive, functional and neuroimaging had positive data
and were statistically significant.
o Initiation of a second, concurrent Phase III study of GAMMAGARD (Immune
Globulin) for mild-to-moderate Alzheimer's disease to complement its ongoing
Phase III trial and to confirm the Phase II results in more patients.
The launch of GLASSIA
TM
[Alpha1-Proteinase Inhibitor (Human)] in the U.S.
GLASSIA
TM
is the first available ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-
PI) and is indicated as a chronic augmentation and maintenance therapy in adults with
emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT).
The initiation of a Phase III clinical trial evaluating the use of ARTISS [Fibrin Sealant
(Human)] in facial surgery in the United States.
Continued research on combining Baxters TISSEEL [Fibrin Sealant] with
complementary technology to potentially regenerate skin and bone.

From Hospital to the Home
Innovation to expand therapies for chronic conditions and by using new and existing
technologies.
Continued research of a new home hemodialysis platform to provide another option for
patients seeking home dialysis for end-stage renal disease.
The advancement of Phase III clinical trial for HyQ, an immunoglobulin therapy
facilitated subcutaneously by recombinant human hyaluronidase a dispersion and
permeation enhancer for patients with primary immune deficiency (PID). The
technology enables patients with PID to self-administer a full dose of IG treatment with
one injection, once a month.
The initiation of a global Phase II trial studying the safety and tolerability of BAX 817,
an on-demand recombinant Factor VIIa therapy for patients with hemophilia A or B with
an inhibitor. BAX 817 is an oral non-anticoagulant sulfated polysaccharide (NASP) being
investigated for adjunctive therapy for hemophilia patients.
The initiation of a Phase I dosing study in healthy subjects of BAX 513, an oral non-
anticoagulant sulfated polysaccharide (NASP) being investigated for adjunctive therapy
for hemophilia patients. BAX 513 involves a novel pharmaceutical approach for
improving hemostasis in bleeding.
The Advancement of a Phase I research study for the use of recombinant von Willebrand
factor (rVWF) for use in patients with type 3 and severe type 1 von Willebrand disease.
People with von Willebrand disease have a deficiency in or impairment of a protein
called von Willebrand factor, an important component in the blood clotting process. As a
result, it takes longer for blood to clot and for bleeding to stop in people with von
Willebrand disease.

Advancing Innovation
Improving technologies to benefit the patient with an improved quality of life via improved
quality of therapy and providers by making medicine more efficient and productive.
The SIGMA SPECTRUM large volume infusion pump met several milestones in the
market including integration with Intermountain Healthcares 23 hospitals throughout
Utah and southeastern Idaho allowing for bi-directional, continuous wireless connectivity
between the pump and the healthcare systems electronic medical record (EMR) system
across its organization. The system allows healthcare providers to see order information
the doctor or pharmacist requested directly on the infusion pump's display screen during
programming.
The approval of PREFLUCEL seasonal influenza vaccine manufactured using Baxter's
proprietary Vero cell technology.

Baxter's Core Technical Competencies
Baxter has six core technical competencies that differentiate the company and provide
competitive advantages in the marketplace. Each represents a specialized area of technical
expertise and leadership that enable the company to develop and manufacture unique healthcare
products. Baxter has well-established and recognized core technical competency in the following
areas:
Medical Plastics
Biologics
Drug Delivery
Solutions
Sterilization
Hardware & Software Development
Medical Plastics
Baxter revolutionized blood collection decades ago when it introduced the first flexible plastic
blood-collection container, paving the way for the first flexible plastic IV solution container for
intravenous (IV) therapy, which became and continues to be the industry standard. Soon to
follow were the MINI-BAG container systems for IV drugs, and the flexible plastic containers
used in peritoneal dialysis, the first portable dialysis therapy. Today, medical plastics are integral
to many Baxter product lines. FLEXBUMIN, the first and only albumin packaged in a flexible
plastic container, is the result of combining Baxters expertise in medical plastics with its
expertise in biologics to create a truly unique product in the marketplace. Baxters expertise in
multi-chamber bags and parenteral nutrition (PN) products lead to the launch of the OLIMEL
container system in Europe.

Biologics
Baxters groundbreaking work in the processing and separation of blood plasma and its
components is at the foundation of many contemporary biologically derived therapies, including
treatments for hemophilia and primary immune deficiency. Baxter also is involved in leading-
edge research and development in recombinant therapeutics, vaccines and regenerative medicine.
Baxter offers unique capabilities in the production of genetically engineered therapies and
vaccines in a variety of bacterial, yeast and mammalian cell culture systems; and protein-based
processes to perform biological separation and purification.

Drug Delivery
Baxter introduced the first premixed drugs in IV solution containers, and was the first company
to form alliances with pharmaceutical companies to package their drugs in IV containers and
provide them to hospitals in premixed form. Today, Baxters drug delivery expertise extends
beyond premixed drugs and drug-reconstitution systems to include formulating and packaging
injectable drugs in vials and syringes, and advanced drug formulation technologies.

Solutions
As manufacturer of the worlds first commercial IV solutions, Baxters expertise in the
formulation, production and purification of solutions extends back 80 years. Since then, Baxter
has applied its expertise in solutions to develop a variety of therapies, including parenteral
nutrition and peritoneal dialysis. Therapeutic solutions such as these may seem basic, but in fact
present a variety of scientific and technical challenges including stability, chemical degradation,
compatibility of ingredients and precipitation. Baxter uses a variety of techniques to overcome
these challenges and ensure quality, consistency and ease of use.

Sterilization
Baxter has pioneered and utilized a range of sterilization platforms to meet the unique
requirements and characteristics of its biopharmaceutical, IV and intravenous and injectable
pharmaceutical and medical device products. These technologies include the use of steam or
heat, ethylene oxide, gamma and electron-beam radiation to sterilize finished product, and the
use of proprietary in-line technologies for aseptic manufacturing. Baxters technology is the only
commercially available aseptic filling process for premixed drugs in flexible IV bags. In 2005,
Baxter combined this proprietary flexible plastic container technology with its expertise in
biologics to introduce the worlds first albumin (a plasma-based protein) in a flexible plastic
container. Baxters sterilization capabilities include systems for validation and assurance, and
development of novel chemical and biological indicators and barrier technologies.

Hardware and Software Development
Baxter also offers unique capabilities in the design, development and integration of hardware and
electronic systems and the software that controls them. Many of the therapies that the company
has pioneered over the years including the administration of IV and dialysis solutions require
the use of a device for the controlled delivery of fluids. Baxter also incorporates human factors
(the manner in which a clinician or patient interacts with or uses a device) into the design of
products to ensure ease of use, and safe and effective delivery of therapy.



Our BioScience business is a leader in recombinant and plasma-based protein replacement
therapies to treat hemophilia and other bleeding disorders; plasma-based therapies to treat
immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and
acute blood-related conditions; products and developmental technology used in adult stem-cell
therapies; and vaccines.
Our Medical Products business manufactures products used in the delivery of fluids and drugs to
patients. These include intravenous (IV) solutions and administration sets, premixed drugs and
drug-reconstitution systems, IV nutrition products, infusion pumps, and inhalation anesthetics, as
well as products and services related to pharmacy compounding, drug formulation and packaging
technologies. The business also is a leading provider of products and services for peritoneal
dialysis, a home-based therapy for people with end-stage kidney disease, and other products used
in dialysis therapy. Sales from businesses within Medical Products were $7.2 billion in 2010 and
represented approximately 56 percent of Baxter's annual sales.
Baxters Medical Products business manufactures products used in the delivery of fluids and
drugs to patients. These include intravenous (IV) solutions and administration sets, premixed
drugs and drug-reconstitution systems, IV nutrition products, infusion pumps, and inhalation
anesthetics, as well as products and services related to pharmacy compounding, drug formulation
and packaging technologies. The business also is a leading provider of products and services for
peritoneal dialysis, a home-based therapy for people with end-stage kidney disease, and other
products used in dialysis therapy. Sales from businesses within Medical Products were $7.2
billion in 2010 and represented approximately 56 percent of Baxters annual sales.
IV Solutions and Premixed Drugs
IV Infusion Systems and Administration Sets
Parenteral Nutrition Products
Anesthesia
Drug and Drug Formulation Technologies
Pharma Partnering
Renal Products and Services
IV Solutions and Premixed Drugs
Baxter is the worlds leading manufacturer of commercially prepared IV solutions as well as
frozen and ready-to-use premixed drugs in flexible IV containers. Baxters portfolio of IV
solutions and premixed drugs is the broadest in the industry. Baxter introduced the worlds first
flexible, closed-system IV container systems, helping to reduce the potential for air contaminants
that can contaminate the solutions and cause infections.

IV Infusion Systems and Administration Sets
Baxter is a recognized leader in IV medication delivery, providing a range of infusion pumps, IV
tubing and access devices to control the delivery of IV fluids and drugs to patients. Baxter
provides electromechanical infusion pumps used in hospitals and other acute-care settings, as
well as portable devices used in oncology and pain management. Baxter pumps enable clinicians
to deliver a wide range of infusion rates to accommodate use throughout the hospital, from the
neonatal unit to the emergency room, and offer features that allow caregivers to establish limits
for specific drugs to enhance patient safety and help reduce medication-programming errors.

Parenteral Nutrition Products
Nutrition administered intravenously is called parenteral nutrition and provides life-sustaining
support for patients who cannot receive adequate nutrients through other means. Baxters
products for parenteral nutrition include solutions, container systems, admixing technology and
vitamin and mineral formulas. In Europe and Canada, Baxter has introduced the first triple-
chamber bag for parenteral nutrition, enabling clinicians to administer appropriate nutrition to
patients in a safe, convenient and cost-effective manner at the point of care. Baxter continues to
expand its portfolio and presence in the parenteral nutrition marketplace through new product
offerings, as well as expanded manufacturing capabilities.

Anesthesia
Anesthesia has played a major role in making surgery a viable option in healthcare, and
represents one of Baxters fastest-growing businesses. Baxter is a leading provider of inhaled
anesthetics for general anesthesia and the only company to offer all three modern inhaled
anesthetics.

Drug and Drug Formulation Technologies
Baxter is also a leader in injectable drugs, offering a broad portfolio of critical medications.
Baxter also offers distinctive labeling as an extension of its drug safety initiatives intended to
assist clinicians in selecting the correct medications and concentrations of its medications.

Pharma Partnering
Baxter applies its drug delivery expertise to contract manufacturing of pre-filled injectable drugs
in vials and syringes, lyophilized drugs and biologics, such as proteins and antibodies, for
pharmaceutical and biotechnology companies. Baxter is the parenteral contract services leader of
pre-filled syringes in North America and is one of the leading parenteral contract manufacturers
worldwide. In 2010, Baxter was named "Best Contract Manufacturing Organization" at the
Vaccine industry Excellence Awards.

Renal Products and Services
Baxter is a leader in renal home therapies through its products for peritoneal dialysis (PD),
providing PD solutions, devices, related supplies and services to help patients with end-stage
kidney disease perform dialysis treatment at home. Baxter also manufactures products and
provides support services for Continuous Renal Replacement Therapy (CRRT), an acute,
hospital-based therapy, and distributes products for in-center hemodialysis (HD).





Corporate address:
One Baxter Parkway
Deerfield, IL 60015-4625

Switchboard
Phone: 847-948-2000




Products and Services

United States
Phone: 800-422-9837 (800-4Baxter)
Fax: 800-568-5020

International
Phone: +1-847-948-4770
Fax: +1-847-948-3642

Business hours: 8am-5pm CT
With 80 years of industry-leading experience, Baxter has won numerous industry, sustainability,
employer, and environment, health and safety awards. Recent awards and honors include:
2011 Great Place to Work in Poland - Great Places to Work Institute - Poland
2011 Great Place to Work in Spain - Great Places to Work Institute - Spain
2011 Great Place to Work in Switzerland - Great Places to Work Institute - Switzerland
2011 Great Place to Work in Netherlands - Great Places to Work Institute - Netherlands
2011 Great Place to Work in Austria - Great Places to Work Institute - Austria
2011 Great Place to Work in France - Great Places to Work Institute - France
2011 Great Place to Work in Portugal - Great Places to Work Institute - Portugal
2011 Great Place to Work in Ireland - Great Places to Work Institute - Ireland
2011 Top 50 Employers - Equal Opportunity Magazine
2010 Great Place to Work in Denmark - Great Places to Work Institute - Denmark
2010 Best Company to Work For - Actualidad Econmica - Spain
2010 36 Employer of Choice - Report (+) PLUS - Austria
2010 Top 50 Companies to Work For CAREERS & the disABLED Magazine
2011, 2010, 2009 100 Best Corporate Citizens Corporate Responsibility magazine
2010, 2009 Baxter Tops Healthcare Category in Newsweek Green Rankings
2009 Catalyst Award Baxter Asia Pacific Region
2009 Worlds Most Ethical Companies Ethisphere Institute
2009 Most Shareholder Friendly Companies Institutional Investor
2009 36 Best Companies for Women to Work in Mexico Great Places to Work
Institute Mexico
2009 20 Best Employers in Puerto Rico Hewitt Associates and
PricewaterhouseCoopers
2008 One of the Best Places to Work in Argentina Apertura Magazine
2008 Best Companies for Women to Work in Mexico Great Places to Work Institute
Mexico
2008 100 Best Companies to Work for in Mexico Great Places to Work Institute
Mexico
2008 50 Best Places to Work in Ireland Great Places to Work Institute Ireland
The 1930s
1931 - The company is founded as the first manufacturer of commercially prepared intravenous (IV) solutions.
1933 - During its first two years, the company distributed products manufactured by another company in Los Angeles
owned by Dr. Don Baxter. But as demand grew in the Midwest, the need for a more central manufacturing base
became apparent. In 1933, the company opened its first manufacturing facility in a renovated automobile showroom
in Glenview, Illinois. There, six employees turned out the complete line of five IV solutions in glass containers.
1935 - The young company prospered and its products earned a reputation for safety and effectiveness, giving
physicians new confidence in IV therapy. In 1935, Dr. Ralph Falk purchased Dr. Baxters interest in the company. He
also developed a research-and-development function to continue the companys pioneering advances in medical
technology. Strong commitment to R&D remains the key to the companys future success.
1939 - In 1939, the company, now named Baxter Laboratories, introduced the Transfuso-Vac container, the first
sterile, vacuum-type blood collection and storage unit. Before this breakthrough product, blood could be stored for
only a few hours; the new container allowed storage for up to 21 days, making blood banking practical for the first
time.
Top
The 1940s
1941 - When World War II broke out, many of Baxter's IV and blood-collection products were the only ones to meet
the specifications of the U.S. Armed Forces. Temporary plants opened to meet increased demand.
Also in 1941, Baxter introduced the Plasma-Vac container, providing the first means of separating plasma from
whole blood and storing it for future use.
1944 - Early in the '40s, a Dutch physician named Willem Kolff began searching for a way to use dialysis, the process
by which particles pass through a membrane, to treat patients with kidney failure. In 1944, his work resulted in the
Kolff rotating drum kidney, the first machine to remove waste materials successfully from the blood through dialysis.
Constructed of wood slats and a cellophane membrane, the Kolff artificial kidney required extensive setup and took
over six hours to perform dialysis.
1945 - A young patent lawyer named William B. Graham joined the company as vice president and manager, and in
1953, succeeded founder Ralph Falk as chief executive officer (CEO). Baxter established one of the most
outstanding growth records in American industry during Mr. Graham's tenure as CEO. In 1945, sales exceed $1.5
million.
1947 - The company moved from its Glenview facility to a larger plant and headquarters in Morton Grove, Illinois.
1948 - Dr. Carl Walter, a noted Boston surgeon and co-founder of Fenwal Laboratories, invented the non-breakable
Blood-Pack plastic blood-collection container.
Top
The 1950s
1950 - The company grew quickly and began increasing production capacity while introducing new products and
expanding internationally. In 1950, the company opened its second U.S. manufacturing plant in Cleveland,
Mississippi.
1952 - Baxter acquired Hyland Laboratories, the first U.S. company to make human plasma commercially available.
1953 - William B. Graham was named president and chief executive officer, and Baxter began a string of 25
consecutive years of more than 20-percent annual earnings growth.
1954 - The company opened an office in Belgium.
1956 - Seeking a medical company that would help develop his kidney dialysis machine (essentially made up of
orange juice cans and a washing machine), Dr. Willem Kolff found an ally in Mr. Graham, who was intrigued by the
product and saw its possibilities. By 1956, Baxter medical engineers had improved the original construction and
Baxter introduced the first commercially built artificial kidney, making life-saving dialysis possible for people with end-
stage renal disease.
1959 - Baxter acquired Fenwal Laboratories. The unit's BLOOD-PACK flexible, plastic container system for collecting
and processing whole blood later led to Baxter's development of the VIAFLEX plastic IV bag, another major
innovation in IV therapy. The technology was applied eventually to the development of a flexible, plastic container
system for dialysis solutions that made possible continuous ambulatory peritoneal dialysis (CAPD), another Baxter
first.
In the late '50s, Baxter formally established an international division to sell Baxter products around the world. Today,
approximately 60 percent of Baxter sales come from non-U.S. markets.
Top
The 1960s
A long-term relationship between Baxter and American Hospital Supply Corporation ended. American had been the
primary distributor of Baxter products since the 1930s. For the first time, Baxter became committed to its own U.S.-
based sales team.
1961 - Baxter stock began trading on the New York Stock Exchange. During the '60s, Travenol (from inTRAVENous
sOLutions) was added to the company name and the Travenol "flag" was introduced.
1962 - Baxter introduced the first disposable blood oxygenator, making open-heart surgery possible.
1968 - Baxter introduced the first commercially produced factor VIII concentrate to treat hemophilia.
1969 - Baxter opened its Round Lake, Illinois research facility.
Top
The 1970s
1970 - The company introduced the VIAFLEX flexible, plastic IV container, a major advance in IV therapy because it
allowed the infusion of IV solution within a closed system, reducing the chance for contamination.
Also in 1970, construction began on a new manufacturing facility in Marion, North Carolina, to supply IV solutions in
Baxter's new VIAFLEX IV bags. Today, the North Cove plant is among the largest IV solutions plants in the world.
1971 - Baxter joined Fortune magazine's listing of the 500 largest American corporations. Sales for the year reached
$242 million.
1975 - The company moved into its current corporate headquarters in Deerfield, Illinois.
1978 - Baxter introduced CAPD as a practical home-based alternative to hemodialysis. The company's sales for the
year exceeded $1 billion.
1979 - The company introduced the first automated blood-cell separator.
Top
The 1980s
1980 - Vernon R. Loucks Jr. became president and chief executive officer, succeeding William B. Graham.
1983 - Baxter introduced the first heat-treated factor VIII concentrate for hemophilia, reducing risk of viral
transmission.
1985 - Baxter acquired American Hospital Supply Corporation, becoming a broad-based healthcare products
distributor in addition to a developer of medical technologies.
1988 - Baxter introduced HEMOFIL M, the first factor VIII purified by chemical and monoclonal technologies.
Top
The 1990s
1991 - The company introduced the INTERLINK IV Access System, the first "needleless" system for IV therapy,
protecting healthcare workers from needle-stick accidents.
1992 - Baxter introduced RECOMBINATE Antihemophilic Factor (recombinant), the first genetically manufactured
factor VIII concentrate.
1994 - Baxter introduced the HOMECHOICE automated peritoneal dialysis machine, a compact, user-friendly device
that cleanses the patients blood overnight.
Baxter opened a new plant in Singapore to manufacture peritoneal dialysis (PD) solutions for the Asian market.
1995 - Baxter gained approval in Europe for its ISOLEX CD34+ stem-cell separator.
Baxter opened a plant in China to manufacture PD solutions for the Chinese market.
1996 - Baxter announced plans to open two more plants in China, these to manufacture IV solutions for the Chinese
market.
Baxter spun off its medical products distribution business as Allegiance Corporation, renewing its focus on its core
technologies of renal technology, biotechnology, and medication delivery.
Baxter received clearance from the U.S. Food and Drug Administration (FDA) for its new COLLEAGUE volumetric
infusion pump, designed to provide accurate, cost-effective IV infusion for a broad range of therapies.
1997 - Baxter acquired Immuno International AG, an international leader in infectious disease research and the
development of blood products, related biologics and vaccines.
1998 - Baxter acquired Ohmedas Pharmaceutical Products Division from The BOC Group, the North American
leader in the production of inhalation agents and drugs used for general and local anesthesia.
Baxter received approval from the FDA to market its TISSEEL Fibrin Sealant in the United States, indicated to
promote hemostasis and wound-sealing in surgery.
Baxter received approval from the FDA to manufacture RECOMBINATE Antihemophilic Factor (recombinant) at its
new biotechnology facility in Thousand Oaks, California.
Baxter introduced the first "triple chamber bag" for total parenteral nutrition.
1999 - Harry M. Jansen Kraemer, Jr., became chief executive officer, succeeding Vernon R. Loucks Jr.
Baxter introduced HomeChoice PRO with PD Link, an advanced at-home kidney dialysis system designed to improve
the care of people with chronic kidney failure by using advanced computer technology to automatically monitor and
communicate critical therapy data from a patient's home to his or her physician.
Top
The 2000s
2000 - Baxter spun off of its cardiovascular business as a separate, publicly traded entity under the name of Edwards
Lifesciences.
Baxter joined four other leading healthcare companies to create the Global Healthcare Exchange, an independent,
Internet-based company that facilitates the exchange of information related to buying, selling and distributing medical
equipment, devices and healthcare products and related services worldwide.
Baxters North Cove, NC, facility received the Shingo Prize for Excellence in Manufacturing.
Baxter completed acquisition of Columbia, Maryland-based North American Vaccine.
2001 - Baxters Mountain Home, Arkansas, facility is named a recipient of the prestigious Shingo Prize for Excellence
in Manufacturing.
Baxter acquired Cook Pharmaceutical Solutions, a manufacturer of prefilled injectable drugs in vials and syringes.
Baxter announced that it would participate in the production of approximately 155 million doses of smallpox vaccine
for the U.S. government, in conjunction with Acambis Inc.
2002 - Baxter received clearance from the FDA to market the Accura Hemofiltration System for continuous renal
replacement therapy (CRRT).
Baxter received FDA approval of EXTRANEAL PD solution, a non-glucose-based solution that provides increased
fluid removal for some dialysis patients.
2003 - Baxter launched its ENLIGHTENEDHRBC bar code technology for flexible IV containers.
The FDA approved ADVATE, the first recombinant factor VIII concentrate for hemophilia made without any added
human or animal proteins in the cell culture, purification and final formulation process, eliminating the risk of infections
caused by viruses that may be carried in these proteins.
Baxter acquired certain assets from Alpha Therapeutic Corporation, including ARALAST, a plasma-based therapy to
treat alpha-1 antitrypsin deficiency.
2004 - Baxter received regulatory approval to market ADVATE in Europe.
Baxter's board of directors elected Robert L. Parkinson, Jr. as the company's new chairman and chief executive
officer.
Baxter and Halozyme Therapeutics entered into an exclusive sales and marketing agreement to commercialize
HYLENEX, a recombinant form of human hyaluronidase that increases the spreading and absorption of other
subcutaneously injected fluids and drugs.
2005 - Baxter received approval from the FDA for GAMMAGARD LIQUID for patients with immune-system disorders.
Baxter introduced FLEXBUMIN, the first albumin in a flexible, plastic container.
Baxter launched the inhalation anesthetic, Sevoflurane.
2006 - Baxter commemorated 75 years of leadership and innovation in healthcare. Baxter made Shanghai, China, the
new location for its Asia Pacific regional headquarters.
The FDA approved ADEPT Adhesion Reduction Solution for use in gynecological laparoscopic procedures.
2007 - Baxter introduced the first needle-less IV connector with an antimicrobial coating.
2008 - Baxter received a positive opinion from regulatory authorities in Europe for CELVAPAN, the first cell culture-
based H5N1 (avian flu) pandemic vaccine.
Baxter received FDA approval of ARTISS fibrin sealant, the first commercially available slow-setting fibrin sealant
used to adhere skin grafts in burn patients.
2009 - Baxter launches HYLENEX recombinant human hyaluronidase in the United States for use in pediatric
hydration, providing a subcutaneous alternative to intravenous administration of fluids.
Baxter opens new headquarters in Zurich, Switzerland, for its Europe, Middle East and Africa (EMEA) region.
The European Commission grants marketing authorization for Baxter's CELVAPAN H1N1 pandemic influenza
vaccine.
Baxter launches OLIMEL, the company's latest triple-chamber container system for parenteral nutrition, in France and
Switzerland.
2010 - Baxter receives regulatory approval in Austria and the Czech Republic for PREFLUCEL seasonal flu vaccine.
Baxter combines its Medication Delivery and Renal businesses to form a new business called Medical Products.
Baxter opens new R&D facility in Alliance Park, Belgium.

PHARMACEUTICAL SOLUTION INDUSTRIES LTD. (PSI)
In the Industrial Estate of Jeddah, Saudi Arabias commercial capital lies one
of the Kingdoms biggest manufacturing enterprises pharmaceutical solution
Industries (P.S.I.). In cooperation with Fresenius, the leading German
company, P.S.I. is based on the most advanced technology to produce life-
saving intravenous fluids, dialysis solutions and oral feeding solutions. The
factory of P.S.I. was built in 1980, and the commercial production was started
in September 1983. More details about the company and its products can be
requested from the Medical Representative, DR SAMER AL OTAIBI by
contacting him at psi@qatarpharmacyest.com or on his mobile phone : +974
5423074 or by calling the Administrative office at +974 4320887/919/909.
Pharmaceutical Solutions


DR SAMER OTAIBI
Mail :psi@qatarpharmacyest.com

METRONIDAZOLE 500 MG SODIUM CHLORIDE 0.18%
DISTILLED WATER 500ML PB WATER FOR INJ
DEXTROSE 25% AMPOULE SOD.CHLORIDE 0.9% IRRIG.
DEXTROSE 50% I.V INF. WATER FOR IRRIGATION
DEXTROSE 5% IN 0.45% NACL MAGNESIUM SULPHATE 50% AMPULES
SODIUM CHLORIDE 0.9% AMPOULES SODIUM CHLORIDE IRRIGATION
SODIUM CHLORIDE 0.9% SODIUM CHLORIDE 0.9% BOTTLES
LIDOCAINE 1% 20/50ML AMPS SODIUM CHLORIDE 0.9% IRRIGATIO
LIDOCAINE 2% W/V 50ML VIAL RINGER SOLUTION
MAGNESIUM SULPHATE 50% DEXTRAN 70 IN DEXTROSE 5%
DEXTROSE 25% AMPOULES DEXTRAN 70 IN NS
DEXTROSE 50% 20 ML AMP. WATER FOR INJECTION
WATER FOR INJECTION AMP DEXTROSE 5% IN 1/2 NS
STERILISED DISTILLED WATER AMP SODIUM CHLORIDE 0.9%
DEXTROSE 5% MINIBAG DEXTROSE 25%
DEXTROSE 50% C.B SODIUM CHLORIDE 0.9%
METRONADIZOLE INFUSION GB SODIUM CHLORIDE 3%
DEXTROSE 5% W/V I.V INFUSION MAGNESIUM SULPHATE 50%
DEXTROSE 5% IN SOD.CHLORIDE SODIUM CHLORIDE 0.9% BAG
SODIUM CHLORIDE 0.9% INFUSION GLYCINE 1.5% FOR IRRIGATION
BABYLITE ORAL SOLUTION MAGNESIUM SULPHATE 10%
RINGER LACTATE COMPOUND SODIUM 1/2 NORMAL SALINE (0.45 SOD.CH
WATER FOR INJECTION 1/2 NORMAL SALINE (0.45 SOD.CH
WATER FOR INJECTION DEXTROSE 5% IN 1/4 NORM.SALINE
WATER FOR INJECTION DEXTROSE 2.5% IN 1/2 NOR.SALIN
POTASSIUM CHLORIDE 15% AMP DEXTROSE 10%
DEXTROSE 50% VIAL CALCIUM CHLORIDE 10%
SODIUM BICARBONATE 8.4% INJ CIPRO-SOL IV 200MG/100 ML
DEXTRAN 40 IN DEXTROSE 5% INJ ATROPINE SULPHATE 0.5MG/1ML
MANITOL 20% SODIUM CHLORIDE 23.4% VIAL